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Abstract
Introduction: Mucopolysaccharidosis VI (MPS VI) is an inherited lysosomal storage disease caused by a mutation of the gene
for arylsulfatase B (ASB). Of the thirty-one patients registered in Germany, almost fifty percent have a Turkish migration
background. MPS VI is treated by enzyme replacement therapy (ERT), which is time-consuming and expensive.
Methods: This interdisciplinary study explored the illness perceptions and clinical treatment experiences among ten MPS VI
patients with a Turkish migration background in two centers for metabolic diseases (Berlin and Mainz, Germany). The clinical
treatment situation was observed and semi-structured interviews were conducted with patients and health care personnel,
in addition to participatory observation in four patients’ everyday environments in Berlin. The data from the interviews,
patient records, and personal field notes were encoded, cross-related, and analyzed.
Results: Patients’ acknowledgement of the disease and coping strategies are influenced predominantly by the perception
of their individual health status and the handling of the disease within their family. Patients’ willingness to cooperate with
treatment strategies is further modified by their knowledge of the disease and the relationships with their health care
providers. In this analysis, cultural factors turned out to be marginally relevant.
Conclusion: As with other chronic and debilitating diseases, effective treatment strategies have to reach beyond delivering
medication. Health care providers need to strengthen the support for patients with a migration background. In this regard,
they should respect the patients’ cultural and social background and their personal perception of the disease and the
therapy. Yet structural and social aspects (clinical setting, family and educational background) may be more crucial here
than ‘‘cultural barriers.’’
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Introduction
Mucopolysaccharidosis VI (MPS VI) is an inherited lysosomal
storage disease (LSD) caused by a mutation of the arylsulfatase B
(ASB) gene that results in reduced activity of the enzyme ASB. The
incidence of MPS VI varies among different populations and
geographic regions, from 1 in 238,000 (Northern Portugal) to 1 in
1,298,000 (British Columbia, Canada) [1] [2] [3] [4] [5]. The
prevalence is estimated to be 1100 patients worldwide [6] [7].
Between 1980 and 1995 thirty-one cases were registered in
Germany. Of these, about fifty percent were patients with a
Turkish migration background [8].
MPS VI is inherited in an autosomal recessive pattern. The high
prevalence in the Turkish population is due to consanguinity, i.e.
intermarriage between cousins, which increases the incidence of
MPS VI in families with a history of the disease [9]. The reduction
of enzyme activity is variable, as is the clinical course of the
disease, currently classified as rapidly or slowly progressing on the
basis of their clinical phenotype and urinary glycosaminoglycan
concentration. While the clinical presentation of patients with
MPS VI demonstrates a continuum of signs and symptoms, a
somewhat stronger genotype/phenotype correlation may be
evident especially in cardiovascular manifestations [10] [11] [12].
The MPS VI phenotype comprises a severe skeletal dysplasia
resulting in short stature and various bone deformations.
Infiltrative cardiomyopathy and respiratory dysfunction are both
due to the storage of glycosaminoglycan (GAG). Corneal opacity
and atrophy of the optic nerve may result in amaurosis, and
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conductive and sensorineuronal hearing loss may lead to deafness.
Coarse facial features, the deformation of hands and feet, as well as
short stature are the visible manifestations of the disease and thus
contribute to the mental distress of patients. MPS VI is not
associated with cognitive impairment and is clinically heteroge-
neous (Table 1). There are large variations with regard to the age
of onset, organ systems affected, and the severity of the disease. In
addition, the rate of disease progression varies widely.
Since 2006, enzyme replacement therapy (ERT, Naglazyme H)
has been available for the treatment of patients with MPS VI.
ERT has to be given intravenously, is generally well tolerated, and
has shown to improve some aspects of MPS VI and may attenuate
disease progression [13] [14].
ERT infusions take up to five hours per week. This is felt as an
inappropriate burden by some patients and they fail to adhere to
the treatment schedule. However, therapeutic efficacy may well
depend on regular and continuous therapy. An irregular treatment
schedule resulting in sub-optimal dosage may significantly reduce
the drug’s therapeutic efficacy, though as no biomarkers are
available to estimate therapeutic efficacy, the effect of suboptimal
dosage over time on the progression of the disease is difficult to
estimate.
In short, repeatedly missed ERT may jeopardize therapeutic
efficacy and put patients at risk. The subsequent lack of positive
effects from irregular ERT may also potentiate patients’ feeling of
the treatment being cumbersome yet inefficient. In addition,
within the clinical setting, patients’ reduced cooperation with the
therapeutic schedule may become a source of potential tension
between health care providers and patients. Medical professionals
might perceive non-adherence to ERT as a ‘‘waste’’ of consider-
able health care resources for ‘‘a non-cooperating’’ patient, as well
as displaying a disregard for their efforts to provide adequate care.
Patients, on the other hand, may not always understand the
medical importance of the treatment and the implications of
missed ERT, and may thus perceive any discussion about their
‘‘cooperation’’ as unjustified.
In spite of these obstacles to care, there has been no research
into the illness perception and treatment experiences of patients
with MPS VI and the ways in which their therapeutic experiences
affect the course and acceptance of therapy. This issue may be
even more important in patients with a migration background, as
they may experience a double exclusion in wider society as well as
within the health system: i) due to having a severe illness, and ii)
because of their migration background.
This study was conducted through cooperation between the
Institute of Social and Cultural Anthropology at the Freie
Universita¨t Berlin and the Centre of Excellence for Rare
Metabolic Diseases at the Charite´-Universita¨tsmedizin Berlin.
We focused on the following issues:
i) What are patients’ understandings of and knowledge
about MPS VI and how do they experience ERT?
ii) How are these aspects influenced by the relationship
between health care providers and patients?
iii) To what extent do cultural factors (such as culturally
shaped understandings of the disease or religious
beliefs) influence the therapy and illness perception?
Table 1. Signs and symptoms of Maroteaux-Lamy syndrome (MPS VI).
Organ Signs and symptoms






Ocular hypertension and glaucoma
Decreased visual acuity and blindness
Optic nerve abnormalities





Systemic vascular narrowing and arterial
hypertension
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iv) How do social aspects such as education, social
background, and family relationships determine the
health behavior of MPS VI patients?
Over the course of five months, an ethnographic study was
conducted investigating patients’ knowledge of MPS VI and their
perceptions of the clinical treatment at two locations in Germany:
i) the Center of Excellence for Rare Metabolic Diseases, Charite´,
Berlin, and ii) the Department of Pediatric and Adolescent
Medicine, Villa Metabolica, University Medical Center, Mainz.
The study also examined the effects of structural differences, i.e.
adult patient versus pediatric care, on the relationships between
patients and health care providers in these two settings. The
qualitative methodology allowed for determining the social,
individual-biographical, and cultural aspects of illness and therapy
perception.
The first part of the article explores the theoretical framework
and explains some of the anthropological concepts used in the
study. Subsequently, the methods and the limitations of the
research are presented. The results are subdivided into patients’
socio-demographic backgrounds, their knowledge of MPS VI,
their perception of ERT, the relationships between patients and
health personnel, and the influence of cultural and social
determinants on illness and therapy perception.
The investigation was performed according to the ethical rules
of the institution referring to the Declaration of Helsinki and Good
Clinical Practice, as well as to the respective EU regulations. All
patients signed an informed content. In addition the aims and
methods of the investigation were individually discussed with the
patients.
Theoretical framework
One fifth of the total German population has a migration
background, but insufficient information is available about their
health conditions and experiences [15]. Few medical or qualitative
studies have explored the relationship between the health status
and health behaviors of migrants in Germany by including
epidemiological as well as social, cultural, and economic factors in
the analysis [16]. This may be due in part to some basic difficulties
encountered by such investigations. First, the definition of the
category of ‘‘migrant’’ often differs among studies. Apart from the
term ‘‘migrant,’’ other designations, such as ‘‘resettler,’’ ‘‘foreign-
er,’’ or ‘‘native speaker,’’ are used [16]. Thus, there is no consensus
on the actual groups to which health-related studies refer [15].
Second, many people described as migrants have had no
personal migration experience, were born in Germany, and have
German citizenship. This does not mean, however, that their
everyday lives and health experiences are not shaped by the fact
that their parents or grandparents settled in Germany as migrants.
Until the year 2004, only those without German citizenship were
officially recorded as ‘‘migrants’’ in Germany. It was not until
2005 that the Federal Department of Statistics introduced the
category ‘‘people with a migration background,’’ which includes
naturalized Germans, their children, ‘‘Spa¨taussiedler’’ (ethnic
German repatriates), and children from bi-national marriages
[17]. The Robert Koch Institut adopted this definition and
comprehends people with a migration background as: i) individ-
uals who have migrated themselves, ii) someone with one parent
who was not born in Germany, or iii) someone for whom both
parents immigrated to Germany and/or do not have German
citizenship [18].
Finally, statistical discrepancies may appear that shed critical
light on previously conducted epidemiological studies on health
and migration. For example, in some cases, even when older
migrants return to their home countries, they still remain officially
registered in Germany, rendering unfeasible the gathering of
reliable mortality statistics [19].
With regard to qualitative research, the risk of overemphasizing
the ‘‘cultural background’’ of migrants in studies on health
behaviors as well as clinical settings has been highlighted by
medical anthropologists. If a migrant’s health behavior is
interpreted as being culturally determined, communication
(linguistic as well as cultural) and translation problems are likely
to be foregrounded and notions of segregation and cultural
difference may be reinforced [20] [21]. This can lead to
stereotyping, while other important determinants such as socio-
structural and individual-biographical factors are not taken into
consideration. Furthermore, while cultural competency is no
doubt required, health care providers should be aware that ‘‘there
is something more basic and more crucial than cultural
competency in understanding the life of the patient, and this is
the moral meaning of suffering–what is at stake for the patient;
what the patient, at a deep level, stands to gain or lose’’ [22].
Building on the insights of existing anthropological and
migration-related investigations, this study assumed that health
and illness behaviors are influenced by the subjective perceptions
and experiences of patients as well as their social, cultural, and
individual-biographical backgrounds. In medical anthropology,
the patient’s subjective experience of ill health or adverse health
events is described by the term illness. It differs from the concept of
disease, which is based primarily on the physical-pathological
dimensions of an ailment [23]. Conscious of this distinction, this
investigation specifically asked whether the socio-cultural factors of
patients with a migration background influenced their subjective
experiences in relation to their illness and health situation, as well
as their coping practices with regard to the biomedically defined
disorder.
Biomedical practice is, furthermore, a cultural system ‘‘of
symbolic meanings, anchored in particular arrangements of social
institutions and patterns of interpersonal interactions’’ [23],
involving negotiation processes between patients and health
professionals that take place in the context of social power
structures [21]. This has an impact on the treatment situation and
on physician-patient communication. Therefore, this study ana-
lyzed the interaction between patients and medical personnel and
the resulting treatment practices, in connection with the structure
of the medical institution. This included, for instance, comparison
of the availability of time and health staff in a setting of adult
patient care (Berlin) versus pediatric patient care (Mainz).
Methods
An ethnographic study was conducted over a period of five
months (May until September 2011), applying the following
methods:
1. Throughout the study, the core method of anthropology,
participatory observation, was used. This means that the
clinical situation, especially the procedure surrounding ERT,
consultations, and treatment encounters, were observed and
analyzed, both in the Center of Excellence for Rare Metabolic
Diseases (hereafter CRMD) in Berlin and the Center for
Lysosomal Storage Disorders (hereafter CLSD) at the Depart-
ment of Pediatric and Adolescent Medicine, Villa Metabolica
in Mainz. The information from the observations was logged in
a field diary. The research also applied direct observations in
the homes and everyday lives of four patients in Berlin in order
to examine their living situation as well as their family and
social networks. This allowed for a deeper insight into the social
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and (potentially) cultural or religious determinants of the
patients’ health behaviors and therapeutic experiences.
2. Semi-structured interviews were conducted with:
i) Eight representatives of the health care providers at the
CRMD, Berlin (average length 30 minutes), in order to
examine their perspectives about patient cooperation (see
Appendix S1).
ii) Six Turkish patients (four in Berlin, two in Mainz), to
explore their clinical treatment experiences and the ways
in which they cope with the illness in their everyday lives.
iii) Four parents (three mothers and one father) of Turkish
patients, as these four patients were too young to be
interviewed.
For the interviews, a narrative approach (focusing on
people’s story-telling about their life experiences) was
applied for the following reasons:
i) Individual illness and therapy perceptions are dependent
on a range of factors (treatment situation, educational
background, family environment, etc.), and the interplay
between them cannot be explored using standardized
methods such as questionnaires.
ii) Due to the low prevalence of MPS VI in Germany, a
quantitative research would not have produced reliable
results.
Based on the clinical observations and preliminary
conversations with patients and medical staff, two
interview guidelines – one for health personnel (see
Appendix S1) and one for patients (see Appendix S2) –
were developed and tested. The guidelines for patients
included questions regarding biographical and socio-
cultural aspects as well as the migration history of the
patients’ respective families. The data gathered during the
patient interviews gave insight into how individual
patients interpreted their illness and perceived the
therapy, and allowed for comparison between patients.
With one exception, the interviews with patients or their
parents (average duration 45 minutes) were held during
their weekly ERT infusion. As all patients had very good
German language skills, the interview language was
German. Due to the age of the patients in Mainz (7 to
23 years), in four cases only their parents were
interviewed. As especially the parents in Berlin had poor
German language skills, informal conversations during
participatory observation in the patients’ homes switched
between German and Turkish. All of the interviews were
recorded with the verbal consent of the interviewed
patients, parents, and health care providers.
3. Throughout the period of data collection, medical records and
the relevant medical and anthropological literature were
reviewed.
4. For analysis purposes, the interviews were transcribed.
Afterwards, the interviews as well as the medical and personal
records from the field diary were coded by identifying the
relevant aspects of the research, cross-related, and finally
analyzed.
5. The patients were recruited from the two largest centres
dealing with inborn errors of metabolism in adults in Germany,
Berlin and Mainz. Inclusion criteria were a genetically
confirmed diagnosis of MPS VI, migration background and
willingness to participate in the interview. No exclusion criteria
were defined. For retrospective data collection ten patients
gave their informed content by signing the treatment contract
with the University Hospital. The contract states that the
patient agrees to have his/her anonymized clinical data
analysed for research purpose. No further ethic application is
needed in this case. For the interviews the patients or their
respective parents were informed about the goals of the
investigation and asked to consent to the interview. This was
documented in the patients’ file.
The Ethical Guidelines of the Charite´ require no ethic
application in case of an interview. The investigation was
performed according to the Declaration of Helsinki (1964 and
amendments up to 2008), the Guidelines of Good Clinical Practice
(GCP 2004) and the Ethical Guidelines of the Charite´. All the
patients interviewed in this study gave their informed consent to
the investigation. The investigation was performed according to
the Declaration of Helsinki (1964 and amendments up to 2008),
the Guidelines of Good Clinical Practice (GCP 2004) and the
Ethical Guidelines of the Charite´.
Limitations of the study
The observations in Mainz and Berlin differed in terms of
intensity and duration. The observations in Mainz were conducted
over a period of one week, while those in Berlin took place over
more than one month, and unlike in Berlin, the social
environments of the patients in Mainz were not observed.
Furthermore, interviews with health care providers were only
conducted at the CRMD in Berlin. Thus, the clinical situation in
Berlin was analyzed more extensively.
The two centers also differed in terms of the type of patients
cared for. While the CRMD in Berlin treats only adult patients
with metabolic diseases, the CLSD in Mainz is a pediatric unit
where the patients’ parents are very much involved by the care
providers. The patients involved in the study thus differed in terms
of age and the level of personal responsibility that they exercise
over their therapeutic situation.
Finally, the researcher’s (L. Leissner) social background, ethnic
identity, as well as personal concern regarding the emotionality of
the medical issue, were a challenge for the data collection. The
following issues were of relevance:
i) It could be assumed that a researcher with the same
cultural background (in this case, of Turkish origin) would
have experienced a greater attitude of openness compared
to a white German researcher in terms of the information
given by the patient participants. However, this assump-
tion was thwarted by a previous experience at the CRMD
in Berlin, where a specifically recruited psychiatrist with a
Turkish background was unable to establish in-depth
communication with the MPS VI patients. This led the
authors of this article to the assumption that the overall
hierarchical nature of the therapeutic setup, in which the
anthropological researcher entered, had an equally strong
impact on the research encounter and the collected data
as the researcher’s own cultural background.
ii) The encounter with people with a severe debilitating
disease personally challenged the researcher, who is not
trained as a medical professional, and so, to a certain
extent, was concerned by the fear and despair expressed
by the patients and their parents. Sometimes sympathy
and solicitousness was verbalized by the researcher during
Illness Perception in Patients with MPS VI
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the interviews, and thus the possibility of this having had
an influence on the answers of the interviewees and on the
data collection in general cannot entirely be ruled out.
Results
Medical, social, religious, and demographic backgrounds
of the patients
Of the ten patients involved in the study, three were male and
seven were female. The age-span of the participants was between 7
and 31 years (Table 2) [24] [12].
The patients were all born in Germany and had similar social
and economic backgrounds. In the course of the labor migration of
the 1960s, the patients’ grandparents had come from urban and
rural areas in Turkey to workforce-demanding regions of West
Germany. The patients’ parents had subsequently found work in
the manufacturing industry or in the service sector. In one case the
father went to university in Germany. At the time of the
investigation, in four cases both of the patients’ parents were
unemployed. Five of the patients were aiming for a General
Certificate of Secondary Education (GCSE) or in the case of three
adults already had one. One was just about to quit school without
a GCSE degree and another had stopped school after finishing the
primary school. Five patients went to schools for physically
disabled people. Two of the six adult patients had finished an
apprenticeship but were unemployed at the time of the research.
Only one woman worked (in a workshop for disabled people). The
interviews showed that the patients experienced little social
mobility in comparison to the previous generation.
Nine patients were Muslim, of which five were Alevi, and one
patient was Yazidi. Two patients lived in a strongly religious
household, while the others practiced religion only on an irregular
basis. All of the four Berlin patients and one patient in Mainz were
children of consanguineous marriages, and all were related to each
other in second or fourth degree – these were the five Alevi
patients.
Only one female patient was living in her own household with
her husband and two children. The other patients had no children
and were living together with their parents and siblings.
Patients’ knowledge about MPS VI
This section explores the knowledge of the patients involved in
the study about the etiology and medical implications of MPS VI.
The patients were diagnosed with MPS VI at a median age of 6
(0–26) years. ERT was initiated at a median age of 13 (4–26) years,
with a mean interval of 8 (0–12) years after diagnosis. Eight of the
ten patients are considered to have a severe form of the disease.
ERT had normalized urinary glycosamin concentration at last
follow-up in seven of the ten patients. Despite this, all patients
demonstrated slowly progressive deterioration.
All but one patient had been diagnosed during childhood and
thus the medical nature of MPS VI had been explained to their
parents. Thereafter, the four adult patients in Berlin claimed that
no further (formal) medical education had been given, neither by
health care providers nor family members. This was confirmed by
two of the interviewed medical doctors in Berlin:
No, I have not done it [explaining MPS VI to the patients]. We always
discussed the individual diagnostic findings and things like performance
and pain but about the disease from the outset, no we have not talked
with them about it. (Medical doctor, Berlin)
Yes of course, in concrete terms you always explained to them what they
are suffering from, which complications exist, why you are doing the
treatment and so on. And when they are always nodding and saying
‘yes, yes,’ you think that they have understood and you assume that they
know, because you have not done the first diagnosis. If they [the
patients] come from a diagnosis and a treatment, you don’t start to
explain everything from the beginning. Probably it’s wrong but, I don’t
know, if they were informed when they came here for the first time, but
maybe that is not sufficient. You assume it. (Medical doctor, Berlin)
Consequently, with one exception, the patients and their
parents in Mainz and Berlin had only marginal knowledge about
the biological causes and repercussions of the disease:
I can’t describe to you what MPS is. (Patient, 27, Berlin)
Four patients and two parents did not know that the disease was
inherited. Furthermore, the patients and their parents had only a
vague understanding of what an inherited disease actually meant:
Table 2. Patients’ social, religious, and demographic backgrounds.
Person Gender Age Location Religion CP Educational level Work
1 male 18 Berlin Muslim (Alevi) yes Primary school unemployed
2 female 26 Berlin Muslim (Alevi) yes Primary school for disabled people working
3 male 27 Berlin Muslim (Alevi) yes GCSE unemployed
4 female 31 Berlin Muslim (Alevi) yes GCSE unemployed
5 female 7 Mainz Muslim no Primary school for disabled people n.a.
6 female 9 Mainz Muslim yes Primary school for disabled people n.a.
7 female 13 Mainz Yazidi no GCSE n.a.
8 female 16 Mainz Muslim no GCSE n.a.
9 female 18 Mainz Muslim yes GCSE for disabled people n.a.
10 male 23 Mainz Muslim (Alevi) yes GCSE for disabled people unemployed
CP - consanguineous parents.
GCSE - General certificate for the secondary educationn.a. - not applicable.
doi:10.1371/journal.pone.0066804.t002
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Yes, it’s coming from the family, but I don’t know why. (Patient, 27,
Berlin)
Most patients could only describe a few symptoms:
Honestly, right now, I don’t know. I can’t describe it myself, I’m only
18 and at 16 I just started to get informed. (…) I have problems with
the blood, as you know, and I have lung problems. Heart problems I do
have. And back pain a lot, I get very confused and, I don’t know, with
which problems to start. (Patient, 18, Mainz)
Five adult patients highlighted that they ‘‘do not want to
understand their disease,’’ because ‘‘it wouldn’t change anything.’’
This phenomenon was observed explicitly among the patients in
Mainz and Berlin who belonged to the same family:
I’ve never talked with them [the health staff] about it. He [the doctor]
tried a few times to explain, but I’ve never wanted to understand what
I’m suffering from. (Patient, 23, Mainz)
You never wanted to understand what you are suffering from?
(Interviewer)
No, I didn’t, no. For what reason? I have it and you can’t change it
anyway, it won’t get any better. (Patient, 23, Mainz)
Taken together, the patients’ knowledge of this complex disease
and its consequences is poor.
The perception of ERT and patient cooperation
The not knowing and not wanting to know about MPS VI had a
particular impact on the perceptions of patients concerning the
treatment and clinical situation. This section describes the
advantages and disadvantages of the therapy from the point of
view of patients and their parents.
In Berlin and Mainz, the MPS VI patients complained about
the duration and frequency of ERT. It has to be kept in mind that
in addition to ERT, the care for patients with MPS VI includes
other regular appointments, such as physio- or speech therapy on
a weekly basis, as well as extensive routine follow-up investigations
once or twice a year such as MRT, ECG, echocardiography,
neurology, etc.:
To come here every Tuesday bothers me. It annoys me (…). If I’m not
in the mood, I call and say that I won’t come. (Patient, 23, Berlin)
At 07:40 a.m., I was here and I had to wait two hours for nothing.
Sometimes it bothers me. (Patient, 26, Berlin)
Often, the child patients have to miss an entire day of school
due to the up to 5 hour long treatment sessions. The therapy poses
a major challenge and mental stress for their parents, too, because
they are forced to organize their everyday lives around the
numerous treatments, appointment, and follow-ups:
Let me put it this way, the therapy itself doesn’t bother me, but coming
here every week bothers me. After some years, it causes nervous
breakdowns, I already had some. (Mother of a patient, 7, Mainz)
She loves going to school, so it’s an extreme burden, that she has to go to
the hospital every Thursday and so she can’t attend the lessons. (Father
of a patient, 13, Mainz)
From the patients’ point of view, the initiation of therapy often
increased hopes and expectations for physical improvement. This,
together with the lack of insight into the character of the disease,
resulted in a significant disappointment when they perceived only
a subsequent stagnation in their health situation. This was
expressed by several patients, for example:
Well, I was fit, so I was thinking, it [the therapy] will be more
effective, and then after some time, I found out that it won’t get better,
and it won’t get worse, it will just stay the way it is. Then I started not
to go. (Patient, 23, Mainz)
In general, there were many diverse perceptions among the
patients regarding the extent of the change in their health
condition brought about by ERT. In particular, this varied in
terms of the progress of the illness and the age of the patient. The
younger patients in Mainz maintained an overall positive attitude
towards the perceived medical effects of the therapy:
In the beginning I recognized that I’m not sick so often anymore and I
grew some centimeters. (Patient, 18, Mainz)
In contrast, all patients in Berlin claimed to be entirely unaware
of any therapeutic benefit:
My mother said I got better from the therapy. Personally I haven’t
noticed it. (Patient, 26, Berlin)
What was common to all the patients in Berlin and Mainz was
that they were not able to explain what kind of medication the
infusion contains:
I really don’t know what’s in there. (…) What kind of medication and
so on, what it does. They said, it’s good for bones, ears, eyes, but I don’t
know exactly. (…) They explained it to me, but I’ve never kept it in
mind. I didn’t care. (…) I think I listened a little bit, and a little bit
not. (Patient, 27, Berlin)
The Berlin patients did not attend ERT regularly – not only
because of the long duration of the infusion, but also because of its
perceived ‘‘ineffectiveness.’’ The overall rate of missed therapy
sessions among the four MPS VI patients in Berlin in the period
from January to September 2011 was 38%. The health care
providers in Berlin assumed that the therapeutic impact would
decrease with low infusion frequency, and thus expressed concern
that this would merely incur high health care costs without benefits
for the patient.
Taken together, the participating patients and their parents’
insight into the medical-technical aspects of MPS VI and ERT is
poor. For several patients, especially those belonging to the same
family in Berlin, the treatment was perceived as ineffective and
cumbersome. Overall, awareness of therapeutic efficacy and
adherence to the treatment sessions were negatively correlated.
Relations between patients and health care personnel
This section describes how the relationships – in terms of
interaction and communication – between the health care
providers and patients affected the experience and perceived
outcome of MPS VI treatment.
The CRMD is part of the Interdisciplinary Centre for
Metabolism at the Charite´, Berlin. It is a University Outpatient
Clinic for adult patients who are cared for by two specifically
assigned physicians. For ERT, the MPS VI patients are referred to
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the department’s day care clinic. There, physicians and nurses are
responsible for a broad range of patients, with little additional time
at their disposal for informal conversations with individual
patients. The MPS VI patients’ supposed main contact is the
physician at the outpatient clinic, who is responsible for their
medical care. Based on an informal conversation with medical
doctors at the CRMD, the clinical interactions with adult patients
aim for: i) ‘‘empowerment’’ of the patient, allowing for a
responsible interaction with an informed patient, as well as ii) a
‘‘non-paternalistic relationship’’ between the health care providers
and patients. All MPS VI patients at the CRMD were transferred
to the adult outpatient clinic via a standardized transition from the
Metabolic Department of the Otto-Heubner Centre for Pediatrics,
Charite´, Berlin.
The CLSD is a Metabolic Unit of the Pediatric Clinic at the
University of Mainz. The physicians and nurses are highly
specialized in the care of metabolic diseases. According to the
needs of children the patient-staff ratio is more favorable than in
Berlin. While the institution is set up specifically to care for
children, due to the regional lack of metabolic care for adults,
patients at the Pediatric Clinic are cared for well into their adult
life. The interviews with the patients and their parents in Mainz
underlined the special trust relationship that is built up with the
medical staff, as many have been in long-term treatment since
childhood.
In the CLSD in Mainz, the general organizational structure of
the facility enables extensive doctor-patient consultation, which
goes beyond purely medical care. Both a nurse and a physician are
exclusively available for the MPS VI patients. Many of the patients
in Mainz have been there since their first diagnosis, and in case of
problems and questions, they contact the clinic first. For patients
and their relatives, it was important to have the feeling of being
able to find help at any time:
If I have any questions, concerns, problems, I can call there at any time
and everybody knows, who is on the phone. (Mother of a patient, 7,
Mainz)
In Berlin, the relationship between medical staff and patients
was characterized by a greater personal and emotional distance
than in Mainz. The health professionals perceived patients’
attitudes during the consultations as passive and claimed that
they just ‘‘spoke on demand.’’ Furthermore, all patients in Berlin
were perceived to be reluctant to talk about personal matters:
I have the feeling the conversations do not go well, the answers are very
short and they don’t talk much, how they feel etc. (Medical staff
member, Berlin)
During the observations of the treatment situation in Berlin, the
researcher also witnessed the patients’ ‘‘silence.’’ The reason given
by these patients for this silence was their fear of saying
‘‘something wrong.’’
In Mainz, on the other hand, the structural conditions at the
CLSD – i.e. the long-term care from childhood into adolescence
and the better ratio of medical personnel to patients – resulted in
individualized care and continuous support for both patients and
their parents.
Social and familial influences on illness and therapy
perception
Apart from the structural conditions of the clinics, the
experience of the illness and the therapy were also affected by
the wider social and familial circumstances of the patients. During
the home observation visits in Berlin, it was noticed that the
subject of the disease was not brought up. The parents did not talk
about it. In one case, the mother did not even want her eighteen
year old son to know about his disease. The siblings of all patients
in Berlin were also not informed about what disease their brother
or sister was suffering from. Even the patients themselves did not
share their experiences and feelings regarding MPS VI with their
family members.
I’m used to it, because at home we don’t talk, outside I don’t talk, also
at work. I also don’t want to speak about it. (Patient, 26, Berlin)
In our family problems don’t exist, we just suppress them. (Patient,
23, Mainz)
One patient expressed the reasons for this ‘‘silence’’:
Because I want to forget, I want to live, how I am now. (Patient, 27,
Berlin)
In Mainz, where in most cases the parents of the MPS VI
patients were interviewed, a more open handling of the disease
was noticed:
We are talking openly about it, because I said, I don’t lie to her. Why
should I hide it from her? She has to grow up with it and finally she has
to live with it. (Mother of a patient, 7, Mainz)
Taken together, it was observed that the way in which patients’
families handle the disease significantly affects the patients’
perception of MPS VI and hence their acceptance of the therapy.
Discussion
This research contributes to current studies on migration and
therapeutic experience among patients with a rare disease such as
MPS VI [9] [25]. It shows that in addition to patients’ individual
knowledge and perception of the disease and its treatment, it is
important to analyze the social and family backgrounds of
patients, as well as the structural situation of the medical facilities
in which they are treated.
Until the introduction of ERT with recombinant human ASB
arylsulfatase (rhASB, galsulfase, Naglazyme H) in 2006, the only
available therapy for MPS VI patients was symptomatic treatment.
Results from a double-blind, placebo-controlled, multi-centre
study with galsulfase [26], and other smaller studies, have
demonstrated improvements in the 12 minute walking and stair
climbing test [27] [28]. In addition, reduction in liver size,
objective improvement in general well being, and reduction on the
pain score have been reported [28]. However, as biomarkers
reflecting therapeutic efficacy are still lacking and final endpoints
take years to develop, the definite benefit of ERT is still a matter of
debate [29]. Complete or even partial remission of all changes
induced by lysosomal storage and the subsequent pathological
processes are not expected. MPS VI is a progressive disease and at
best ERT may predominantly provide stabilization, preventing
further aggravation of the condition.
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Aside from the medical evidence of the results of ERT,
therapeutic efficacy is greatly influenced by patients’ expectations
and acceptance of the therapeutic regimen. Yet so far there has
been no research on the illness perception and treatment
experiences of patients with MPS VI, and on the ways in which
their therapeutic experiences affect the course and acceptance of
therapy. This study used an interdisciplinary approach by
integrating medical and anthropological aspects and demonstrated
that patients’ behavior vis-a-vis the therapy and how they cope
with their illness can be explained by an interplay of various
factors.
Patients’ knowledge about MPS VI
The patients’ knowledge about the disease was generally poor,
as was their understanding of the ERT. MPS VI is a complex
disease and difficult to understand for persons with a non-medical
professional background, even with repeated information given to
patients about the disease, therapy, and the need for follow-up.
Two principal reasons for this knowledge deficit in the patients
could be demonstrated: firstly the lack of encompassing informa-
tion about MPS VI and ERT given by health personnel and
secondly because of the patients ‘‘not wanting to know’’ about
their illness. Furthermore, in the clinical setting in Berlin, even
when medical aspects were not fully understood, the patients did
not dare to ask. They seemed intimidated by the difference in
status between themselves and the medical staff and the
acknowledgement that they probably did not ‘‘correctly’’ under-
stand the medical information. This may have resulted in a self-
perception of inferiority in relation to the health care providers.
The analysis below shows that this ‘‘silence’’ concerning and the
‘‘not-knowing’’ about MPS VI is closely related not only to the
therapeutic conditions in the clinical settings, but also to social
aspects, for example how the disease is managed within patients’
families.
The perception of ERT and patient cooperation
Medical aspects play an important role in terms of cooperation
and illness perception. The clinical picture, such as like the severity
of symptoms, determines significantly a patient’s self-perception in
relation to their illness of the patients. When the patients in this
study suffered from few symptoms and the disease was morpho-
logically less visible, they often perceived themselves as healthy and
of having only minor constraints in their everyday lives. Therefore,
if the conditions of the therapy – such as the frequency, duration,
and notable efficacy of ERT – are perceived as a burden, this can
reduce therapy acceptance. On the other hand, even if patients do
experience many severe and visible symptoms, and perceives
themselves as ill, the lack of subjectively measureable improve-
ments brought about by the burdensome ERT schedule may also
have a negative impact on therapy acceptance.
Relations between patients and health care personnel
The structure of the health care facility was found to have a
significant impact on the patient-physician relationship, and
consequently on the perception of, as well as the cooperation
with, therapy. Time and staff availability in the hospitals are
crucial in order to provide successful treatment and build up a
relationship of trust with patients. The example of the CLSD in
Mainz demonstrates that due to the individually focused and
extensive care of patients, therapy acceptance is high. On the
other hand, the lack of both time and health care personnel in the
CRMD in Berlin had a negative impact on patient cooperation. It
has to be kept in mind, however, that in the pediatric facility in
Mainz it is the parents who are responsible for keeping up with the
therapeutic schedules, thus treatment adherence is maintained by
someone who is only indirectly affected by the disease or the
therapy itself, but who is also ultimately responsible for the young
patient’s health. In contrast, in Berlin the responsibility for
treatment adherence lies with the individual adult patient. This
may well partly explain the difference in adherence to the ERT
treatment schedule in favor of Mainz.
Social and familial influences on illness and therapy
perception
Not only the structure of the health care setting but also the
family background is significant for the ways in which patients
manage their disease. These two aspects may also interfere with
each other.
Marschalck and Wiedl [30] argue that patients’ social network,
in this case the family, has an important influence on the way in
which patients deal with the disease, though this is not always in a
positive way. This finding is consistent with Mark Nichter’s
research on the ‘‘social relations of therapy management,’’ in
which he states that: ‘‘The study of therapy management entails
not only what people do (and can do) and reasons for actions
taken, but what they are unable to do and what lies under
apparent passivity, acceptance, or fatalism’’ [31]. The ‘‘silence’’
about MPS VI within the family in Berlin resulted in a suppression
of discussion and a passive handling of the disease. It explains why
the patients did not want to understand their illness [32]. In this
case, not wanting to know can be a sign of a particular illness
perception and illness behavior, and further it can be assumed that
this aspect will reduce the willingness of patients to accept
treatment. In particular, patients’ insistence on ‘‘not wanting to
know’’ may be perceived in the medical encounter as a ‘‘wall of
silence,’’ and the health care providers may therefore experience
difficulties in building up a relationship of trust and communica-
tion with these patients.
Unfortunately, due to the small number of patients in the study,
we were not able to arrive at a definitive conclusion concerning the
effect of the family and health care structures on the perceptions of
and ways of dealing with MPS VI and ERT – and the way these
individually reported perceptions and ways of coping do (not)
reflect a larger cultural pattern. In particular, since all four of the
patients in Berlin (and one in Mainz) were from the same family,
some of the challenges faced in Berlin may well be related to the
specific socio-familial dynamics among this group of patients
where the practice of intermarriage, especially between cousins,
existed. Thus, the physicians in Berlin reported that there are
currently about eleven cases of MPS VI in this one family.
According to family members, the other five relatives with MPS
VI live in Turkey. Probably as a defense mechanism to cope with
shame and guilt about the disease, the family members did not talk
about it. This self-protection has likely developed out of fear of
stigmatization of the family. The fact that cases of MPS VI had
accumulated within the family over generations, combined with
mutual loyalty and the shared fear of outside stigma, have led to
silence about the illness as a dominant way of coping among family
members. This is supported by the fact that even though all but
one of these five related patients were severely affected by the
disease from a medical perspective, it was important for them to be
perceived as healthy by others and to have a ‘‘normal’’ life.
Furthermore however, the dynamics of ‘‘silent coping’’ may have
been reinforced by the fact that the family members in Berlin and
the patient in Mainz have an Alevi background. In the Muslim
world, Alevis are often exposed to the accusation of ‘‘incest’’ and
their affiliation to the Islamic community is denied [33]. This
particular situation may possibly increase these patients’ experi-
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ence of double marginalization: due to their status as migrants and
within the larger Muslim community on the one hand [34] [35]
[36], and as MPS VI patients on the other.
The way in which problems are dealt with, or rather not dealt
with, within this family may therefore be a coping strategy induced
by their marginalization, as well as by a feeling of shame and guilt
that has been expressed by some family members [37]. This family
strategy of avoiding the problem of MPS VI may well shape the
ways in which the patients themselves handle their disease. Thus
the familial (and potentially also the religious) background of these
patients has to be taken into account and it is evident that
additional psycho-social support may be needed to allow for
effective medical therapy.
Perceptions of health care providers
It is of interest to note that the health care providers in Berlin
were aware of the particular difficulties in dealing with this group
of patients. However, they perceived the patients as ‘‘foreign,’’ and
thought that an anthropological investigation would be necessary
in order to understand them. According to their understanding, an
in-depth investigation into the ‘‘intercultural problems’’ of these
patients would possibly help both the patients and the health care
providers improve their mutual cooperation. However, if a
migrant’s health behavior is interpreted solely as being culturally
determined, this is likely to lead to stereotyping, while other
important determinants such as socio-structural and individual-
biographical factors are not taken into consideration [20]. In the
case of the Berlin family, social and family structures – possibly
reinforced by their cultural background as Turkish Alevis – were
more important in shaping the patients’ health care behavior than
the fact of their migration background per se.
In summary, medical and social components, such as family
background and the structure of health facilities, had an important
yet varying impact on patients’ therapy perception and individual
health attitude. Our data show that cultural factors (such as
religious background) may have reinforced specific ways of coping
with MPS VI illness, but were not necessarily central to the ways in
which patients handled the disease, and could be neglected in the
analysis (see Figure 1). Finally, the influence of educational
background on patients’ knowledge about MPS VI may well have
shaped their subjective illness perceptions and the patient-
physician relationship. This latter aspect needs to be explored in
further comparative research with larger samples of interviewees.
To conclude, the following four aspects could lead to an
improvement of the clinical situation for people with a chronic
disease such as MPS VI, and thus increase the willingness of
patients to receive therapy and improve the relationships between
patients and health professionals:
N The lack of knowledge among MPS VI patients about the
disease has important consequences for the perception of the
therapy and the clinical situation. Patients and their families
need to be informed about MPS VI during the therapy on a
regular basis, because patients’ perceptions about the disease
shift over time. There should be specific courses for patients
that include family members, held by Turkish speaking health
Figure 1. Determinates influencing individual health progress (source: authors).
doi:10.1371/journal.pone.0066804.g001
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personnel, where appropriate, because – in contrast to the
patients in this study – especially the parents in Berlin had
usually insufficient German language skills. The relatively low
educational level of the patients and their parents could be one
reason why they had such minimal knowledge about MPS VI,
but due to the small sample size, further research is needed to
verify this hypothesis. Nonetheless, with regards to the relating
of clinical and disease-related information to patients, the
educational background of patients should be taken into
consideration and an appropriate didactic concept should be
applied.
N Despite the fact that German hospitals face financial
restrictions, the recruitment of additional nursing staff to care
for patients with a chronic condition should be considered, in
order to ensure the best care possible. In this regard, health
providers should respect the patients’ cultural and social
background and their personal perception of the disease and
the therapy. Yet structural and social aspects (clinical setting,
family and educational background) may be even more crucial
here than ‘‘cultural barriers.’’
N The number of doctor-patient discussions should be increased
to build up a relationship of trust. The setup, in which a
layperson meets the expert in a consultation, may lead to the
patient feeling intimidated during the interaction. While this is
potentially true for every patient-physician interaction, it may
have a greater impact in interactions with patients who feel
themselves already marginalized due to their disease, migrant
status, and lack of formal education. Health care providers
should be aware of their status as ‘‘respected persons’’ and
should try to adapt to the educational background of patients
during the communication of medical details. Health care
providers should also acknowledge that MPS VI patients suffer
from mental distress. A foundation of trust for successful
therapy is therefore essential.
N To understand patients’ clinical experiences and illness
perceptions, this study concludes that further interdisciplinary
research, including anthropological and medical aspects,
should be conducted to improve the treatment of patients
with a migration background suffering from rare metabolic
diseases. In particular, future research should pay more
attention to the influence of a patients’ social network,
especially the family, on illness and treatment perception, as
well as its impact on the therapeutic outcome.
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